Vitiligo activity and prognosis blood test study
Part of Skin clinical trials.
This study uses a simple blood test to measure immune system signals (cytokines) that may indicate whether vitiligo is active or stable. The goal is to create a model that helps predict how the disease may progress.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a confirmed diagnosis of vitiligo, or be a healthy volunteer for comparison.
- You cannot have used antibiotics, steroids, or immune-suppressing medications in the past month.
- You must not have serious health conditions like heart disease, diabetes, infection, skin cancer, or autoimmune disorders.
- You cannot be pregnant or breastfeeding.
- You must be willing and able to follow study procedures and attend follow-up visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether special particles derived from umbilical cord stem cells can help restore skin color in vitiligo (a condition causing loss of skin pigmentation). The treatment is being tested in adults with vitiligo affecting 1–30% of their body.
This study looks at inflammation in people with vitiligo, psoriasis, atopic dermatitis, or alopecia areata. It aims to understand how these conditions compare, which may lead to better treatments.
This study looks at differences in the gut and skin microbiome (the germs living in and on the body) in people with vitiligo and in people without vitiligo. It aims to understand what might be linked to how vitiligo spreads over time.
This study tests a new medicine called LY4005130 for non-segmental vitiligo, a skin condition where patches lose pigment (color). The trial aims to see if this drug can help restore skin color and stop the spread of white patches.
This trial tests a daily pill (upadacitinib) to see if it can improve vitiligo after an initial treatment (NECS). It is for people whose vitiligo is stable and covers a limited area.
This study tests a new medicine called FB102 for people with non-segmental vitiligo. It aims to see if the drug is safe and helps restore skin color.
Hear when a new Vitiligo trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.